T. Plenge
University of Cologne
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by T. Plenge.
Journal of the American College of Cardiology | 2018
T. Plenge; Johannes Terporten; Alexandra C. Maul; Arian Sultan; Jakob Lueker; Jan van den Bruck; Anja Sterner-Kock; Daniel Steven; Dennis Ladage
Ventricular arrhythmias are the main driver of mortality in ischemic cardiomyopathy. Inhomogeneous left ventricular remodeling after myocardial infarction is a prediscribed pathophysiology of macro reentry mechanisms within the scar. Vital and recovering myocytes form channels of slow conduction
International Journal of Cardiology | 2018
Christian-Hendrik Heeger; Barbara Bellmann; Thomas Fink; Jan-Eric Bohnen; Erik Wissner; Peter Wohlmuth; Laura Rottner; Christian Sohns; Roland Richard Tilz; Shibu Mathew; Bruno Reissmann; Christine Lemes; Tilman Maurer; Jakob Lüker; Arian Sultan; T. Plenge; Britta Goldmann; Feifan Ouyang; Karl-Heinz Kuck; Ilka Metzner; Andreas Metzner; Daniel Steven; Andreas Rillig
BACKGROUND The prevalence of atrial fibrillation (AF) increases with age. Second-generation cryoballoon (CB2)-based PVI has demonstrated encouraging clinical results in the treatment of paroxysmal (PAF) and persistent atrial fibrillation (PersAF). The objective of this study was to assess data on safety, efficacy and long-term clinical success of CB2-based pulmonary vein isolation (PVI) in patients ≥75 years of age. METHODS CB2-based PVI was performed in 104 patients ≥75 years of age (elderly group) and symptomatic AF (PersAF: n = 44, 42.3%) in three highly experienced German EP centers. The data was compared to propensity score matched patients with age <75 years (n = 104, control group; PersAF: n = 45, 43.3%, p = 0.956). RESULTS The median age of the elderly group was 77.5 [75, 80] years while it was 63 [52, 70] years of control group patients (p = 0.0001). The median procedure time was 92.5 [75, 120] minutes (elderly group) and 100 [75, 120] (control group), p = 0.124. Major complications were registered in 7/104 (6.7%) elderly patients and 7/104 (6.7%) control group patients (p = 0.999). Clinical success in terms of freedom from AF recurrence after one-year follow-up was 80% (95% CI: 72-88) and 82% (95% CI: 75-90) and after three-year follow-up 59% (95% CI: 47-74) and 49% (95% CI: 37 64) for the elderly group and the control group, respectively (p = 0.7). CONCLUSIONS CB2-based PVI in patients ≥75 years of age appears safe, is associated with low procedure times and shows promising clinical success rates equal to patients of the younger population.
Herz | 2015
Arian Sultan; Jakob Lüker; T. Plenge; Daniel Steven
Herzschrittmachertherapie Und Elektrophysiologie | 2015
D. Steven; J.-H. van den Bruck; T. Plenge; J. Lüker; A. Sultan
Herzschrittmachertherapie Und Elektrophysiologie | 2018
Jakob Lüker; Arian Sultan; T. Plenge; Samuel Lee; Jan-Hendrik van den Bruck; Daniel Steven
European Heart Journal | 2018
Barbara Bellmann; T. Plenge; Arian Sultan; Daniel Steven
Europace | 2018
Christian-Hendrik Heeger; Barbara Bellmann; Thomas Fink; Shibu Mathew; Bruno Reissmann; Christine Lemes; T Maurer; Francesco Santoro; Arian Sultan; T. Plenge; Feifan Ouyang; K H Kuck; Andreas Metzner; Daniel Steven; Andreas Rillig
Europace | 2018
Christian-Hendrik Heeger; Barbara Bellmann; Thomas Fink; Shibu Mathew; Bruno Reissmann; Christine Lemes; T Maurer; Francesco Santoro; Arian Sultan; T. Plenge; Feifan Ouyang; K H Kuck; Andreas Metzner; Daniel Steven; Andreas Rillig
Clinical Research in Cardiology | 2018
Jakob Lüker; Arian Sultan; T. Plenge; J. van den Bruck; C.-H. Heeger; S. Meyer; K. Mischke; Roland Richard Tilz; D. Vollmann; G. Nölker; B. Schäffer; Stephan Willems; Daniel Steven
Herzschrittmachertherapie Und Elektrophysiologie | 2017
Daniel Steven; Jan-Hendrik van den Bruck; Jakob Lüker; T. Plenge; Arian Sultan
